Published in J Neurol Neurosurg Psychiatry on September 01, 1999
A Multifactorial Exercise Program to Reduce Falls in People With Parkinson Disease | NCT02302144
Incidence and prediction of falls in Parkinson's disease: a prospective multidisciplinary study. J Neurol Neurosurg Psychiatry (2002) 2.61
Impaired regulation of stride variability in Parkinson's disease subjects with freezing of gait. Exp Brain Res (2003) 1.88
The role of oxidative stress in Parkinson's disease. J Parkinsons Dis (2013) 1.86
Gait dynamics in Parkinson's disease: common and distinct behavior among stride length, gait variability, and fractal-like scaling. Chaos (2009) 1.81
Late-stage Parkinson's disease: the Barcelona and Lisbon cohort. J Neurol (2010) 1.41
Predictors of survival in patients with Parkinson disease. Arch Neurol (2012) 1.27
Effect of gait speed on gait rhythmicity in Parkinson's disease: variability of stride time and swing time respond differently. J Neuroeng Rehabil (2005) 1.20
Balance confidence and functional mobility are independently associated with falls in people with Parkinson's disease. J Neurol (2009) 1.18
UPDRS activity of daily living score as a marker of Parkinson's disease progression. Mov Disord (2009) 1.18
The natural history of Parkinson's disease. J Neurol (2006) 1.05
Postural instability and fall risk in Parkinson's disease: impaired dual tasking, pacing, and bilateral coordination of gait during the "ON" medication state. Exp Brain Res (2011) 1.00
Late-stage Parkinson disease. Nat Rev Neurol (2012) 0.97
Prediction of falls and/or near falls in people with mild Parkinson's disease. PLoS One (2015) 0.95
Estimated life expectancy of Parkinson's patients compared with the UK population. J Neurol Neurosurg Psychiatry (2007) 0.89
Home and health in people ageing with Parkinson's disease: study protocol for a prospective longitudinal cohort survey study. BMC Neurol (2013) 0.88
The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease. J Neurochem (2016) 0.85
The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson's disease. J Neurol (2013) 0.84
Audio-biofeedback training for posture and balance in patients with Parkinson's disease. J Neuroeng Rehabil (2011) 0.81
Long-term mortality analysis in Parkinson's disease treated with deep brain stimulation. Parkinsons Dis (2014) 0.81
External validation of a 3-step falls prediction model in mild Parkinson's disease. J Neurol (2016) 0.79
Psychological Benefits of Nonpharmacological Methods Aimed for Improving Balance in Parkinson's Disease: A Systematic Review. Behav Neurol (2015) 0.79
Clinical and Epidemiological Factors Associated with Mortality in Parkinson's Disease in a Brazilian Cohort. Parkinsons Dis (2015) 0.78
Person-Centered Care in the Home Setting for Parkinson's Disease: Operation House Call Quality of Care Pilot Study. Parkinsons Dis (2015) 0.78
Gene Expression Differences in Peripheral Blood of Parkinson's Disease Patients with Distinct Progression Profiles. PLoS One (2016) 0.77
Protocol for a home-based integrated physical therapy program to reduce falls and improve mobility in people with Parkinson's disease. BMC Neurol (2012) 0.76
The association between indicators of health and housing in people with Parkinson's disease. BMC Geriatr (2016) 0.75
Mortality from Parkinson's disease. J Neurol Neurosurg Psychiatry (2000) 0.75
Mortality and Its Risk Factors in Patients with Rapid Eye Movement Sleep Behavior Disorder. Sleep (2016) 0.75
Parkinson's disease: fetal cell or stem cell-derived treatments. BMJ Clin Evid (2015) 0.75
The Natural Progression of Parkinson's Disease in a Small Cohort with 15 Drug-naïve Patients. Chin Med J (Engl) (2015) 0.75
Mortality in Iranian Patients with Parkinson's Disease: Cumulative Impact of Cardiovascular Comorbidities as One Major Risk Factor. Parkinsons Dis (2015) 0.75
Parkinson's disease. BMJ Clin Evid (2007) 0.75
Discriminating cognitive status in Parkinson's disease through functional connectomics and machine learning. Sci Rep (2017) 0.75
Hypometabolism in the supplementary and anterior cingulate cortices is related to dysphagia in Parkinson's disease: a cross-sectional and 3-year longitudinal cohort study. BMJ Open (2013) 0.75
Motion and emotion: anxiety-axial connections in Parkinson's disease. J Neural Transm (Vienna) (2016) 0.75
Parkinsonism: onset, progression and mortality. Neurology (1967) 36.06
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry (1992) 33.67
Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain (1991) 8.16
Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology (1990) 4.41
The impact of treatment with levodopa on Parkinson's disease. Q J Med (1980) 3.14
A method for evaluating disability in patients with Parkinson's disease. J Nerv Ment Dis (1961) 3.14
Does levodopa therapy delay death in Parkinson's disease? A review of the evidence. Mov Disord (1995) 1.93
Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued. Eur J Clin Pharmacol (1992) 1.86
Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project. Neurology (1993) 1.57
Two decades of increasing mortality from Parkinson's disease among the US elderly. Arch Neurol (1990) 1.56
Risk factors for progression in Parkinson's disease. Neurology (1988) 1.49
Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology (1995) 1.46
Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol (1984) 1.34
Parkinson's disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurology (1994) 1.29
The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol (1995) 1.29
Low cancer rates among patients with Parkinson's disease. Ann Neurol (1985) 1.24
Multi-center study of Parkinson mortality with early versus later dopa treatment. Ann Neurol (1987) 1.21
Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men. Neurology (1996) 1.19
Mortality in patients with Parkinson's disease. Acta Neurol Scand (1995) 1.13
Mortality from Parkinson disease. Arch Neurol (1997) 1.09
Effect of physical exercise on mortality in patients with Parkinson's disease. Acta Neurol Scand (1992) 1.09
The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry (1994) 1.07
Survey of disability that is associated with Parkinson's disease. Med J Aust (1988) 1.05
The changing patterns of death rates in parkinsonism. Neurology (1990) 1.05
Effect of L-dopa on course of Parkinson's disease. Lancet (1984) 1.03
Clinical observations on the rate of progression of idiopathic parkinsonism. Brain (1994) 0.99
Parkinson's disease in Aberdeen: survival after 3.5 years. Acta Neurol Scand (1990) 0.97
Does ageing aggravate parkinsonian disability? J Neurol Neurosurg Psychiatry (1991) 0.97
A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson's disease. Neurology (1987) 0.95
Clinical course of patients with idiopathic Parkinson's disease. Mov Disord (1996) 0.94
L-dopa long-term treatment in Parkinson's disease: age-related side effects. Neurology (1983) 0.91
An examination of male-female differences in progression and mortality of Parkinson's disease. Neurology (1990) 0.90
Six years of high-level levodopa therapy in severely akinetic parkinsonian patients. Arch Neurol (1976) 0.90
Young-onset Parkinson's disease: a clinical review. Neurology (1991) 0.89
Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor. Eur Neurol (1976) 0.88
Parkinsonism treated with levodopa: progression and mortality. J Neural Transm Suppl (1983) 0.87
Parkinson's disease mortality: preliminary report. Adv Neurol (1990) 0.86
The natural history of Parkinson's disease. Neurology (1996) 0.85
Age at onset: the major determinant of outcome in Parkinson's disease. Acta Neurol Scand (1995) 0.85
Levodopa in Parkinson disease: a long-term appraisal of mortality. Ann Neurol (1978) 0.84
Mortality of patients with Parkinson's disease treated with levodopa. J Neurol (1977) 0.81
Parkinson's disease mortality in Italy, 1951 through 1987. Analysis of an increasing trend. Arch Neurol (1993) 0.80
Cholera. Clin Microbiol Rev (1995) 12.33
Cholera and other vibrioses in the United States. N Engl J Med (1985) 5.17
Bacteriophage therapy. Antimicrob Agents Chemother (2001) 5.16
Oxygen and the growth and metabolism of Clostridium acetobutylicum. J Gen Microbiol (1971) 4.91
Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infect Immun (1988) 4.44
Emerging foodborne pathogens: Escherichia coli O157:H7 as a model of entry of a new pathogen into the food supply of the developed world. Epidemiol Rev (1996) 4.09
Harlequin syndrome: the sudden onset of unilateral flushing and sweating. J Neurol Neurosurg Psychiatry (1988) 3.47
Phenotypic evaluation of acapsular transposon mutants of Vibrio vulnificus. Infect Immun (1990) 3.47
Non-O group 1 Vibrio cholerae gastroenteritis in the United States: clinical, epidemiologic, and laboratory characteristics of sporadic cases. Ann Intern Med (1981) 3.25
Learning and memory difficulties after environmental exposure to waterways containing toxin-producing Pfiesteria or Pfiesteria-like dinoflagellates. Lancet (1998) 3.03
Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans. J Clin Invest (1987) 3.03
A new route of transmission for Escherichia coli: infection from dry fermented salami. Am J Public Health (1996) 2.78
Vibrio cholerae O139 synonym bengal is closely related to Vibrio cholerae El Tor but has important differences. Infect Immun (1994) 2.73
The fibre size and content of the radial and sural nerves. J Neurol Neurosurg Psychiatry (1968) 2.65
Evaluation of DNA colony hybridization and other techniques for detection of virulence in Yersinia species. J Clin Microbiol (1989) 2.58
Production of Solvents by Clostridium acetobutylicum Cultures Maintained at Neutral pH. Appl Environ Microbiol (1984) 2.51
Back pain: a randomized clinical trial of rotational manipulation of the trunk. Br J Ind Med (1974) 2.47
Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains. Infect Immun (1995) 2.45
Cloning of the cytotoxin-hemolysin gene of Vibrio vulnificus. Infect Immun (1985) 2.42
On the permeability to weak acids and bases of the cytoplasmic membrane of Clostridium pasteurianum. Biochem Biophys Res Commun (1981) 2.32
The capsule and O antigen in Vibrio cholerae O139 Bengal are associated with a genetic region not present in Vibrio cholerae O1. Infect Immun (1995) 2.25
Illness caused by Vibrio damsela and Vibrio hollisae. Lancet (1982) 2.17
Isolation of vancomycin-resistant enterococci from animal feed in USA. Lancet (1999) 2.12
Distribution of Vibrio vulnificus in the Chesapeake Bay. Appl Environ Microbiol (1996) 2.10
Non-O:1 Vibrio cholerae bacteremia: case report and review. Rev Infect Dis (1988) 2.07
Half-time and high-speed running in the second half of soccer. Int J Sports Med (2012) 2.03
Cloning and sequence of a region encoding a surface polysaccharide of Vibrio cholerae O139 and characterization of the insertion site in the chromosome of Vibrio cholerae O1. Mol Microbiol (1996) 2.01
A study of a brucellosis epidemic. Ir J Med Sci (1970) 1.99
Comparison of DNA probes and the Sereny test for identification of invasive Shigella and Escherichia coli strains. J Clin Microbiol (1986) 1.96
Utilization of L-threonine by a species of Arthrobacter. A novel catabolic role for "aminoacetone synthase". Biochem J (1969) 1.95
Comparative genomic analysis of the gut bacterium Bifidobacterium longum reveals loci susceptible to deletion during pure culture growth. BMC Genomics (2008) 1.94
Rapid identification of Vibrio vulnificus on nonselective media with an alkaline phosphatase-labeled oligonucleotide probe. Appl Environ Microbiol (1993) 1.94
Identification of environmental Vibrio vulnificus isolates with a DNA probe for the cytotoxin-hemolysin gene. Appl Environ Microbiol (1987) 1.94
The extracellular cytolysin of Vibrio vulnificus: inactivation and relationship to virulence in mice. Infect Immun (1991) 1.87
Non-O1 Vibrio cholerae NRT36S produces a polysaccharide capsule that determines colony morphology, serum resistance, and virulence in mice. Infect Immun (1992) 1.86
Superoxide dismutase in some obligately anaerobic bacteria. FEBS Lett (1975) 1.85
Purification and determination of the structure of capsular polysaccharide of Vibrio vulnificus M06-24. J Bacteriol (1992) 1.81
The cytolysin gene of Vibrio vulnificus: sequence and relationship to the Vibrio cholerae E1 Tor hemolysin gene. Infect Immun (1990) 1.79
Facial sweating in Horner's syndrome. Brain (1984) 1.73
Investigation of an outbreak of Salmonella enteritidis gastroenteritis associated with consumption of eggs in a restaurant chain in Maryland. Am J Epidemiol (1988) 1.71
Development and testing of a nonradioactive DNA oligonucleotide probe that is specific for Vibrio cholerae cholera toxin. J Clin Microbiol (1992) 1.71
Molecular techniques in the study of Salmonella typhi in epidemiologic studies in endemic areas: comparison with Vi phage typing. Am J Trop Med Hyg (1986) 1.68
Seroprevalence of Helicobacter pylori in Seventh-Day Adventists and other groups in Maryland. Lack of association with diet. Arch Intern Med (1990) 1.68
Improved pulsed-field gel electrophoresis for typing vancomycin-resistant enterococci. J Clin Microbiol (2000) 1.66
Cholera in Lima, Peru, correlates with prior isolation of Vibrio cholerae from the environment. Am J Epidemiol (1997) 1.65
Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study. J Neurol Neurosurg Psychiatry (1968) 1.65
Vibrio metschnikovii bacteremia in a patient with cholecystitis. J Clin Microbiol (1981) 1.65
Seroprevalence of Helicobacter pylori in Chile: vegetables may serve as one route of transmission. J Infect Dis (1993) 1.59
Identification of a group 1-like capsular polysaccharide operon for Vibrio vulnificus. Infect Immun (2001) 1.58
Effect of metronidazole on hydrogen production by Clostridium acetobutylicum. Arch Mikrobiol (1972) 1.57
How general practitioners assess risks in using new drugs. J R Coll Gen Pract (1975) 1.56
Spo0A directly controls the switch from acid to solvent production in solvent-forming clostridia. Mol Microbiol (2000) 1.55
Mutations in the extracellular protein secretion pathway genes (eps) interfere with rugose polysaccharide production in and motility of Vibrio cholerae. Infect Immun (2000) 1.50
The neuropsychology of de novo patients with idiopathic Parkinson's disease: the effects of age of onset. Int J Neurosci (1989) 1.49
The polyneuropathy of chronic renal failure. Brain (1971) 1.49
Detection by immune electron microscopy of 27-nm viral particles associated with community-acquired diarrhea in children. J Infect Dis (1990) 1.48
Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease. Arch Neurol (2000) 1.47
Capsular types of Vibrio vulnificus: an analysis of strains from clinical and environmental sources. J Infect Dis (1993) 1.47
Fatal Diabetic Ketosis. Br Med J (1961) 1.46
Use of colistin-polymyxin B-cellobiose agar for isolation of Vibrio vulnificus from the environment. Appl Environ Microbiol (1992) 1.45
Persistence of cholera in the United States: isolation of Vibrio cholerae O1 from a patient with diarrhea in Maryland. J Clin Microbiol (1986) 1.44
Chlorine and survival of "rugose" Vibrio cholerae. Lancet (1992) 1.43
Patient-to-patient transmission is important in extended-spectrum beta-lactamase-producing Klebsiella pneumoniae acquisition. Clin Infect Dis (2007) 1.43
Myocardial failure in cats associated with low plasma taurine: a reversible cardiomyopathy. Science (1987) 1.42
Handcuff neuropathy involving the dorsal ulnar cutaneous nerve. Muscle Nerve (1993) 1.40
An outbreak of cholera in Maryland associated with imported commercial frozen fresh coconut milk. J Infect Dis (1993) 1.39
Confusion, cortical blindness and fever. Med J Aust (1995) 1.38
Nystagmus retractorius and progressive ataxia in a young man: clinicopathological conference. Med J Aust (1990) 1.38
The biosynthesis of granulose by Clostridium pasteurianum. Biochem J (1974) 1.37
Phylogeny of Vibrio cholerae based on recA sequence. Infect Immun (2000) 1.37
Differential expression of Vibrio vulnificus capsular polysaccharide. Infect Immun (1999) 1.36
Isolation of nontoxigenic Vibrio cholerae O group 1 from a patient with severe gastrointestinal disease. J Clin Microbiol (1984) 1.35
Non-O group 1 Vibrio cholerae gastroenteritis associated with eating raw oysters. Am J Epidemiol (1981) 1.35
Epidemiology and spectrum of Vibrio infections in a Chesapeake Bay community. J Infect Dis (1989) 1.31
Blood glucose variations and clinical experience with glibenclamide in diabetes mellitus. Br Med J (1970) 1.30
The stage is set for the diffusion of positron emission tomography (PET) in oncology. Med J Aust (1999) 1.30
Utilization of L-threnonine by a pseudomonad: a catabolic role for L-threonine aldolase. Biochem J (1969) 1.29
Purification of two Clostridium bacteriocins by procedures appropriate to hydrophobic proteins. Antimicrob Agents Chemother (1975) 1.28
Pyruvate carboxylase in Rhodopseudomonas spheroides. J Gen Microbiol (1969) 1.27
Vibrio vulnificus septicemia. Isolation of organism from stool and demonstration of antibodies by indirect immunofluorescence. Arch Intern Med (1983) 1.26
Molecular epidemiology of neonatal meningitis due to Citrobacter diversus: a study of isolates from hospitals in Maryland. J Infect Dis (1986) 1.23
The proton-translocating adenosine triphosphatase of the obligately anaerobic bacterium Clostridium pasteurianum. 1. ATP phosphohydrolase activity. Eur J Biochem (1979) 1.23
Vibriocidal antibody responses in North American volunteers exposed to wild-type or vaccine Vibrio cholerae O139: specificity and relevance to immunity. Clin Diagn Lab Immunol (1997) 1.23
Epidemiology of antimicrobial resistant cholera in Kenya and East Africa. Am J Trop Med Hyg (1988) 1.22
Distal chronic spinal muscular atrophy involving the hands. J Neurol Neurosurg Psychiatry (1978) 1.21
The adoption of new drugs by doctors practising in group and solo practice. Soc Sci Med (1975) 1.21
Regeneration of protoplasts of Clostridium pasteurianum ATCC 6013. J Bacteriol (1983) 1.20
Development of an in vitro model for study of non-O1 Vibrio cholerae virulence using Caco-2 cells. Infect Immun (1990) 1.20
Fifth Stenhous-Williams memorial lecture. Oxygen and the obligate anaerobe. J Appl Bacteriol (1976) 1.19
Proton-motive force in the obligately anaerobic bacterium Clostridium pasteurianum: a role in galactose and gluconate uptake. FEBS Lett (1975) 1.19
A video review of the diagnosis of psychogenic gait: appendix and commentary. Mov Disord (1999) 1.18
Evaluation of using a short region of the recA gene for rapid and sensitive speciation of dominant bifidobacteria in the human large intestine. FEMS Microbiol Lett (1997) 1.17
Lack of hepatic enzymatic adaptation to low and high levels of dietary protein in the adult cat. Enzyme (1977) 1.17
Carbohydrate digestion by the domestic cat (Felis catus). Br J Nutr (1977) 1.16
Release of tumor necrosis factor alpha in response to Vibrio vulnificus capsular polysaccharide in in vivo and in vitro models. Infect Immun (1997) 1.15
Typhoid fever in Santiago, Chile: a study of household contacts of pediatric patients. Am J Trop Med Hyg (1984) 1.15
Clinical features of ciguatera fish poisoning: a study of the disease in the US Virgin Islands. Arch Intern Med (1982) 1.14